MSL
MRTX

Mackay Shields LLC’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Mackay Shields LLC’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,200
Closed -$2.26M – 1407
2021
Q1 		$2.26M Sell
13,200
-8,100
-38% -$1.6M 0.02% 721
2020
Q4 		$4.68M Sell
21,300
-1,800
-8% -$389K 0.03% 502
2020
Q3 		$3.84M Sell
23,100
-2,200
-9% -$301K 0.03% 512
2020
Q2 		$2.89M Buy
25,300
+7,200
+40% +$698K 0.02% 598
2020
Q1 		$1.39M Sell
18,100
-300
-2% -$26.9K 0.01% 821
2019
Q4 		$2.37M Sell
18,400
-800
-4% -$77.2K 0.02% 802
2019
Q3 		$1.5M Buy
19,200
+300
+2% +$28.2K 0.01% 1018
2019
Q2 		$1.95M Buy
+18,900
New +$1.47M 0.01% 905

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Mackay Shields LLC's MRTX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 13,200 shares — an estimated $2.26M sold.

Mackay Shields LLC first reported a position in MRTX in Q2 2019 and held it in 8 quarters. The position peaked at $4.68M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 13,200 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $2.26M.
  • Mackay Shields LLC first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Mackay Shields LLC's Mirati Therapeutics, Inc. Common Stock position peaked at $4.68M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.